Skip to main content
. 2018 Jan 1;9(2):250–255. doi: 10.7150/jca.22318

Table 2.

Clinical Outcome

All patients (N=13)
Best response on lenvatinib (N)
Complete response 0
Partial response 4
Stable disease 4
Progressive disease 1
not evaluable 4
Duration of lenvatinib treatment (months) - median (range) 5 (1-18+)
Ongoing (N) 6
Terminated (N) 7